Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Status:
RECRUITING
Trial end date:
2028-07-31
Target enrollment:
Participant gender:
Summary
This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Obinutuzumab may also reduce the risk of immune-related conditions from treatment. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals cancer cells to multiply. Giving glofitamab in combination with pirtobrutinib may be safe, tolerable and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.
Phase:
PHASE2
Details
Lead Sponsor:
C. Babis Andreadis
Collaborators:
Adaptive Biotechnologies Eli Lilly and Company Genentech, Inc.